Creating new drugs to reduce amyloid production in Alzheimer's disease
Official title: Development of Small-Molecule Degraders of APP as the first-in-class drugs for Alzheimer's therapy
Funded at Degrome Therapeutics, INC. · NIH-11007789 · Data updated 2026-11-12
This study is exploring new medications that can help lower harmful proteins in the brain linked to Alzheimer's disease by using special cells from patients, with the hope of creating better treatments for those affected by the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Degrome Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $499,883 |
| NIH project number | 1R41AG090241-01 |
| Project ID | NIH-11007789 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease who may benefit from new therapeutic options targeting amyloid production.
✕Less likely to help
Patients with other forms of dementia or those not diagnosed with Alzheimer's disease may not receive any benefit from this research.
What this research studies
This research focuses on developing small-molecule degraders that target amyloid precursor protein (APP) to reduce the production of amyloid beta (Aβ) peptides, which are implicated in the progression of Alzheimer's disease. By utilizing induced pluripotent stem cells from Alzheimer's patients, the researchers aim to create novel therapeutics that can effectively degrade APP and lower Aβ levels in the brain. The approach involves innovative drug discovery techniques that recruit harmful proteins for destruction, potentially leading to a new class of Alzheimer's treatments.
Why it matters
Potential benefit: If successful, this research could lead to the first effective treatment for Alzheimer's disease by significantly reducing amyloid beta levels in the brain.
How similar studies have gone: While many clinical trials targeting amyloid have failed, recent successes with new monoclonal antibodies suggest that targeting the amyloid cascade remains a promising therapeutic strategy.
Where this research is happening
-
Degrome Therapeutics, INC.
Indianapolis, United States Active
Researchers
- Principal investigator: Hao, Chunhai Charlie — Degrome Therapeutics, INC.
- Study coordinator: Hao, Chunhai Charlie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.